Heron Therapeutics (NASDAQ:HRTX) reported 3/31/2018 earnings this Morning, coming in at ($0.81) per share, beating Wall Street’s estimates of ($0.87) per Share. Revenue for the quarter came in at $11.60 million beating analyst estimates of $11.10 million Recent Insider Trading for Heron Therapeutics (NASDAQ:HRTX)
- On 3/29/2018 Kevin C Tang, Director, bought 192,308 with an average share price of $26.00 per share and the total transaction amounting to $5,000,008.00.
- On 3/19/2018 Barry D Quart, CEO, sold 100,000 with an average share price of $29.75 per share and the total transaction amounting to $2,975,000.00.
- On 3/19/2018 Kimberly Manhard, VP, sold 18,000 with an average share price of $30.00 per share and the total transaction amounting to $540,000.00.
- On 3/14/2018 Barry D Quart, CEO, sold 100,000 with an average share price of $24.75 per share and the total transaction amounting to $2,475,000.00.
- On 1/10/2018 Kimberly Manhard, VP, sold 7,584 with an average share price of $20.00 per share and the total transaction amounting to $151,680.00.
- On 4/24/2017 Kimberly Manhard, VP, sold 21,542 with an average share price of $15.33 per share and the total transaction amounting to $330,238.86.
Dividend History for Heron Therapeutics (NASDAQ:HRTX)
Recent Trading for Heron Therapeutics (NASDAQ:HRTX) Shares of Heron Therapeutics closed the previous trading session at 30.85 up +0.45 1.48% with shares trading hands.